Common name
pyrazine
IUPAC name
pyrazine
SMILES
c1nccnc1
Common name
pyrazine
IUPAC name
pyrazine
SMILES
c1nccnc1
INCHI
InChI=1S/C4H4N2/c1-2-6-4-3-5-1/h1-4H
FORMULA
C4H4N2
Common name
pyrazine
IUPAC name
pyrazine
Molecular weight
80.088
clogP
1.189
clogS
-0.927
Frequency
0.0024
HBond Acceptor
2
HBond Donor
0
Total PolarSurface Area
25.78
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00077 | Bortezomib |
|
Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C8 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; | For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
| FDBD00224 | Pyrazinamide |
|
Antitubercular Agents; Antimycobacterials; Antiinfectives for Systemic Use; Drugs for Treatment of Tuberculosis; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP3A4 Inhibitors; | For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. |
| FDBD00529 | Sulfametopyrazine |
|
Antimalarials; Anti-Infective Agents; Anti-Infective Agents, Urinary; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Sulfonamides and Trimethoprim; Long-Acting Sulfonamides; | For the treatment of urinary tract infection and chronic bronchitis. |
| FDBD01369 | Telaprevir |
|
Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; CYP3A4 Inhibitors; | Treating chronic hepatitis C virus (genotype 1) infection in patients with compensated liver (due to liver diseases like cirrhosis) that are treatment naive or have failed therapy with interferons (either null or partial responders and treatment relapsers). |
| FDBD01831 | Selexipag |
|
Antihypertensive Agents; Antithrombotic Agents; Blood and Blood Forming Organs; Platelet Aggregation Inhibitors Excl. Heparin; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; CYP3A4 Inhibitors; | Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. |
| FDBD02231 | pyrafluprole |
|
Insecticide | Insecticide |
| FDBD02937 | pyraziflumid |
|
Fungicide | Fungicide |
7 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1qy2_ligand_frag_1.mol2 | 1qy2 | 1 | -5.72 | c1nccnc1 | 6 |
| 3at3_ligand_frag_0.mol2 | 3at3 | 1 | -5.72 | n1ccncc1 | 6 |
| 3at4_ligand_frag_0.mol2 | 3at4 | 1 | -5.72 | n1ccncc1 | 6 |
| 1qy1_ligand_frag_0.mol2 | 1qy1 | 1 | -5.70 | n1ccncc1 | 6 |
| 2nnd_ligand_frag_0.mol2 | 2nnd | 1 | -5.70 | n1ccncc1 | 6 |
| 4qye_ligand_frag_1.mol2 | 4qye | 1 | -5.68 | c1nccnc1 | 6 |
| 3e3b_ligand_frag_0.mol2 | 3e3b | 1 | -5.66 | n1ccncc1 | 6 |
| 4wrs_ligand_frag_2.mol2 | 4wrs | 1 | -5.59 | c1cnccn1 | 6 |
247 ,
25
